Your browser is no longer supported. Please, upgrade your browser.
Settings
GEMP Gemphire Therapeutics Inc. daily Stock Chart
GEMP [NASD]
Gemphire Therapeutics Inc.
Index- P/E- EPS (ttm)-2.90 Insider Own11.90% Shs Outstand10.47M Perf Week5.74%
Market Cap99.26M Forward P/E- EPS next Y-2.72 Insider Trans0.00% Shs Float5.71M Perf Month1.72%
Income-33.90M PEG- EPS next Q-0.66 Inst Own32.20% Short Float9.83% Perf Quarter22.48%
Sales- P/S- EPS this Y-66.40% Inst Trans7.77% Short Ratio9.62 Perf Half Y-5.48%
Book/sh0.94 P/B10.09 EPS next Y13.60% ROA-130.60% Target Price23.83 Perf Year0.11%
Cash/sh2.42 P/C3.92 EPS next 5Y- ROE-184.10% 52W Range7.20 - 21.59 Perf YTD20.92%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.09% Beta-
Dividend %- Quick Ratio4.20 Sales past 5Y- Gross Margin- 52W Low31.67% ATR0.53
Employees17 Current Ratio4.20 Sales Q/Q- Oper. Margin- RSI (14)49.70 Volatility4.18% 5.76%
OptionableNo Debt/Eq0.00 EPS Q/Q-44.50% Profit Margin- Rel Volume0.33 Prev Close9.50
ShortableYes LT Debt/Eq1.01 EarningsNov 15 Payout- Avg Volume58.36K Price9.48
Recom1.70 SMA20-0.20% SMA50-1.17% SMA200-13.06% Volume19,569 Change-0.21%
Oct-27-17Resumed Piper Jaffray Overweight $22
Oct-19-17Initiated ROTH Capital Buy
Aug-31-17Initiated H.C. Wainwright Buy $21
Aug-08-17Reiterated Jefferies Buy $32 → $18
Apr-10-17Initiated Piper Jaffray Overweight $30
Nov-13-17 01:30PM  Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-02-17 07:00AM  Accomplished BioPharma Executive Mina Sooch Joins BioVie Board of Directors and Purchases Company Stock Marketwired
Oct-23-17 08:00AM  Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017 GlobeNewswire
Sep-25-17 09:00AM  Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit GlobeNewswire
Sep-19-17 04:01PM  Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development GlobeNewswire +5.93%
Sep-18-17 08:00AM  Gemphire to Present at Cantor Fitzgerald Global Healthcare Conference on September 26 in New York GlobeNewswire
Sep-14-17 04:36PM  Gemphire to Host Investor Conference Call to Discuss Future Development Plans for Gemcabene GlobeNewswire
Aug-14-17 06:00AM  Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Aug-07-17 11:57AM  Gemphire Therapeutics Inc. (Nasdaq: GEMP) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire -46.78%
10:00AM  Gemphire to Present at the Canaccord Genuity Growth Conference 2017 GlobeNewswire
06:00AM  Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients GlobeNewswire
Aug-01-17 04:30PM  Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -7.31%
Jul-25-17 08:00AM  Gemphire Enters Into $15 Million Term Loan Agreement With Silicon Valley Bank GlobeNewswire
Jul-14-17 08:15AM  Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 9.7% Zacks
Jun-28-17 04:01PM  Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients GlobeNewswire
Jun-01-17 08:00AM  Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference GlobeNewswire +8.69%
May-31-17 09:41AM  Stocks to Watch: Amazon, Alphabet, Michael Kors, Gemphire Therapeutics The Wall Street Journal
May-30-17 04:01PM  Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch GlobeNewswire
May-09-17 06:00AM  Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
May-04-17 02:21PM  Gemphire to Host Key Opinion Leader Lunch on the Evolving NASH Landscape GlobeNewswire
May-01-17 06:00AM  Gemphire to Present at ATVB|PVD 2017 Scientific Sessions GlobeNewswire
Mar-29-17 04:30PM  Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Mar-24-17 01:04PM  GEMPHIRE THERAPEUTICS INC. Financials
10:48AM  Gemphire Therapeutics (GEMP) is in Overbought Territory: What's Next? Zacks
Mar-23-17 08:35AM  Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 12% Zacks
Mar-21-17 09:17AM  Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization GlobeNewswire
06:06AM  GEMPHIRE THERAPEUTICS INC. Files SEC form 10-K, Annual Report
Mar-16-17 03:52PM  Gemphire to Present at the Oppenheimer Annual Healthcare Conference and the H.C. Wainwright NASH Investor Event GlobeNewswire +5.41%
Mar-15-17 04:30PM  Gemphire Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today
04:08PM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:01PM  Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q4 2016 Gemphire Therapeutics Inc Earnings Release - After Market Close
Mar-13-17 05:10PM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
06:30AM  Gemphire Therapeutics to Report Fiscal Year End 2016 Financial Results on Wednesday, March 15 GlobeNewswire
Mar-10-17 09:34AM  Gemphire Therapeutics Announces $12.5 Million Financing GlobeNewswire
09:26AM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial
Feb-07-17 06:31AM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-03-17 04:24PM  Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides Investor's Business Daily
04:24PM  Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides
Feb-02-17 06:00AM  Gemphire Therapeutics to Participate in the Canaccord Genuity Rare Disease and Biopharma 1 on 1 Day and the RBC Capital Markets Global Healthcare Conference GlobeNewswire
Jan-30-17 06:00AM  Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial GlobeNewswire
Jan-18-17 05:00PM  Gemphire Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-09-17 08:00AM  Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study GlobeNewswire
Jan-05-17 08:40AM  Gemphire Therapeutics Provides Clinical Update GlobeNewswire
Jan-04-17 03:40PM  LifeSci Capital Initiates Coverage of Gemphire Therapeutics Accesswire
Dec-20-16 12:03AM  How Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers at Insider Monkey
Dec-19-16 02:00PM  Three Appealing Micro-Cap Stocks
Nov-29-16 04:15PM  Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-16 11:07AM  CORRECTING and REPLACING Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia GlobeNewswire
06:00AM  Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia GlobeNewswire
Nov-17-16 04:01PM  Gemphire Therapeutics to Present at the Piper Jaffray Healthcare and LD Micro Main Event Conferences GlobeNewswire
Nov-02-16 07:07AM  Q3 2016 Gemphire Therapeutics Inc Earnings Release - Time Not Supplied
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. Its product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. The company was founded in 2008 and is headquartered in Northville, Michigan.